Improving Lives through Affordable Care
Mississippi Obesity Alliance Program
General Information
What is the Mississippi Obesity Alliance Program (MOA)?
The MOA Program is a collaborative initiative by Revival Health and BSS Health to provide affordable GLP-1 medications to Mississippians, addressing the state’s obesity crisis.
​​
Who is involved in this initiative?
Revival Health, BSS Health (co-founded by former Governor Phil Bryant), and statewide health clinics are key partners. Other collaborators include healthcare providers like Sesame, a telehealth marketplace.
Why is this program important now?
Mississippi has some of the highest obesity rates in the U.S. This program offers life-changing obesity treatments at a fraction of the typical cost, addressing both affordability and access issues during a time of nationwide medication shortage, particularly for underinsured or uninsured patients. ​​
​​
When will this program be available?
The Mississippi Obesity Alliance Program is available now. Interested participants can access GLP-1 medications via local clinics or online consultations with licensed clinicians. Ask your local clinic if they're a part of the Mississippi Obesity Alliance Program to ensure quality medication. If they're not, they can reach out to moa@revival.care to join and begin offering affordable, quality anti-obesity medication.
​
How do I get Care?
If I’d like to get care through the MOA program, where do I go?
There are a growing number of clinics joining the MOA program. If you don’t live near a participating clinic, please go to www.sesamecare.com/moa to get remote care.
Program Specifics
What types of medications are being offered?
Revival Health will offer GLP-1 injections and oral medication kits for weight management. These include compounded versions of GLP-1 medications such as Semaglutide Compound.
​​
How much do the medications cost under this program?
You can expect to pay between $179 and $249 for a 2-milliliter supply of GLP-1, compared to the typical price of $800 to $1,100 for brand medication.
Who is eligible for the program?
CLINICS & HOSPITALS - The Mississippi Obesity Alliance (MOA) Program is actively seeking clinics across the state to join this initiative, which aims to combat the growing obesity crisis in Mississippi. Clinics and hospitals of all types, including but not limited to medical weight loss, primary care, endocrinology, women’s health, cardiology, multi-specialty and pain management clinics are welcome to participate. ​
Clinics that join the MOA Program will benefit from access to affordable, quality GLP-1 medications for their patients. Additionally, clinics looking to scale or offer telehealth services may leverage Sesame, an integrated telehealth platform, to evaluate patients remotely and ensure convenient, continuous care for those participating in the program. This makes it easier for clinics to expand their patient base without overburdening in-person services. ​
​By joining the program, participating clinics will receive the necessary support from MOA Program, including training, medication access, and a streamlined process for managing patient eligibility. This partnership also offers an opportunity to collaborate with statewide health organizations, while attracting new patients who may not have otherwise been able to afford these medications.
​
If your clinic is interested in joining the MOA Program, please reach out to learn more about how to participate and bring this life-changing treatment to your community.
​
PATIENTS - Patients with a BMI of 30 and above or BMI of 27 plus a weight related comorbidity is eligible for a prescription from a board certified provider.
​
When does the MOA Program launch?
The Mississippi Obesity Alliance Program (MOA) began its soft launch in September 2024, providing access to affordable GLP-1 medications across a select group of Mississippi healthcare clinics. These clinics, including women’s health, multi-specialty, and pain management centers, have been instrumental in testing the program’s early rollout and refining patient engagement strategies.
The program is now widely available, expanding the reach to more clinics and enabling widespread access to life-changing medications for Mississippians struggling with obesity. This launch will build on the success of the initial rollout, which has already brought affordable treatments to hundreds of patients.
If I’d like to get care through the MOA program, where do I go?
There are a growing number of clinics joining the MOA program. If you don’t live near a participating clinic, you can remote care through a board certified telemedicine provider at www.sesamecare.com/moa.
Health and Industry Impact
​Why is obesity such a pressing issue in Mississippi?
With nearly 70% of adults overweight or obese, Mississippi faces a public health crisis that increases the risk of conditions like diabetes and heart disease.​​
What are GLP-1 medications and why are they effective?
GLP-1 medications help manage blood sugar levels, reduce appetite, and support long-term weight loss by mimicking natural hormones that regulate hunger.
Are these medications FDA-approved?
The medications offered in the program are compounded under FDA regulations, ensuring they meet the highest quality standards.​​
Economic and Supply Challenges
​Why are these medications so expensive elsewhere?
Nationwide demand for GLP-1 drugs has led to higher prices, limited insurance coverage, and supply shortages. Revival Health’s program significantly reduces costs, providing a solution to affordability and access barriers. ​​
How does the Mississippi initiative compare to efforts in other states?
Unlike states that have discontinued insurance coverage for GLP-1s due to high costs, Mississippi’s program offers affordable access regardless of insurance status.
What will Revival Health do if GLP-1 medications come off the FDA shortage list?
Revival Health is committed to ensuring affordable and accessible healthcare solutions for Mississippians, regardless of market conditions. Currently, our program provides access to compounded GLP-1 medications due to the ongoing shortage of these branded drugs, as listed by the FDA.
​
If GLP-1 medications come off the FDA shortage list, we will adhere to regulatory guidelines. In such a case, our focus will shift to maintaining affordability and accessibility through other means.
​
We will continue to explore partnerships and innovative solutions to provide patients with low-cost treatment options. Our commitment to addressing the broader issues of obesity and healthcare access in Mississippi remains steadfast.
Additional Resources
​Where can I find more details about the program?
More information is available at www.revival.care. ​​
Who can I reach out to for more information?
For more information, please contact us at moa@revival.care
Be the first to know!
Sign up to receive more information about MOA as it becomes available.